340B's $60B future hangs on HRSA pilot program
Supply Chain Pulse — 2026-05-06
HRSA's proposed 340B rebate pilot could reshape how hospitals access discounted drugs in a program worth over $60 billion annually, with providers pushing back hard while drugmakers see it as their best shot at accountability. Meanwhile, HHS Secretary RFK Jr. signaled potential changes to site-neutral payments and prior authorizations across his seven congressional hearings this month, adding regulatory uncertainty to an already volatile landscape. Supply chain leaders should expect continued 340B turbulence through 2026 — start modeling alternative procurement scenarios now.
Quick Hits
- FDA clears TaeWoong Medical's Spaxus EUS stent for US commercialization (Medical Device Network)
- Mayo Clinic launches Platform_Accelerate program for digital health startups (Modern Healthcare)
- IHH Healthcare deploys Oracle Fusion Cloud for enterprise system unification (Manila Times)
- Amazon opens logistics network to all businesses, including 3M and Lands' End (Supply Chain Dive)
- France fines Novo Nordisk and Lilly over weight-loss drug advertising (RAPS)
HRSA wants a 340B rebate pilot. Here's what the industry thinks
HRSA's proposed rebate pilot for the $60+ billion 340B program has hospitals and drugmakers on opposite sides, with providers arguing it undermines the program's intent while pharma companies see it as the only path to restore accountability. For supply chain teams, this could fundamentally change how covered entities access discounted drugs and manage pharmaceutical procurement strategies. The pilot's design and timeline will determine whether hospitals need to restructure their drug purchasing models.
How a single word could determine the future of 340B
Legal wrangling over pharmaceutical industry challenges to 340B program rules has created regulatory uncertainty that could impact drug pricing for eligible hospitals and clinics. The outcome of ongoing litigation will determine whether current contract pharmacy arrangements remain viable or if supply chain teams need to develop alternative distribution strategies. Supply chain leaders should monitor these cases closely as decisions could force rapid operational changes to drug procurement workflows.
RFK Jr. signals changes to Medicare Advantage, site-neutral payments
HHS Secretary Robert F. Kennedy Jr.'s congressional testimony revealed potential policy shifts on Medicare Advantage prior authorizations and site-neutral payment policies that could impact hospital reimbursement models. His comments on 340B program oversight suggest increased scrutiny of covered entities' compliance and contract pharmacy relationships. Supply chain teams should prepare for potential changes to both payment structures and drug discount program requirements that could affect procurement budgets.
BD and Wellstar partner to improve hospital medication delivery systems
BD's partnership with Wellstar Health System focuses on enhancing medication delivery safety and efficiency across the health system's facilities, potentially serving as a model for other large health systems. This collaboration could demonstrate ROI benchmarks for medication management technology investments and workflow optimization strategies. Supply chain leaders should track outcomes from this partnership to inform their own medication delivery system evaluations.
Source: Medical Device Network
PBMs lean on private label biosimilars to cut costs, boost profit
Healthcare conglomerates with both insurance and PBM arms are increasingly favoring biosimilars manufactured by their overseas subsidiaries, creating potential conflicts of interest in drug selection. This trend could limit hospital and clinic access to certain biosimilar options while concentrating market power among vertically integrated players. Supply chain teams should evaluate whether their current PBM relationships provide transparent access to the full biosimilar market or favor proprietary products.
Mid-size PBMs fear Labor's transparency mandates will increase costs
Smaller pharmacy benefit managers argue that proposed Labor Department transparency requirements would create disproportionate compliance burdens and operational costs compared to larger competitors. These rules could reshape the PBM market by potentially driving consolidation or forcing mid-size players to exit, reducing hospital and health plan options. Supply chain leaders should assess whether their current PBM partnerships have the resources to meet new transparency requirements without passing costs through to clients.
AHA and West Health commit $12M for hospital technology adoption
The American Hospital Association's partnership with West Health includes $12 million in funding to help hospitals adopt and scale technology-enabled solutions for improved patient care. This initiative could provide benchmarking data on successful technology implementations and ROI metrics for supply chain technology investments. Hospital supply chain teams should monitor which technologies receive funding priority and track implementation outcomes for procurement planning.
Source: Healthcare Purchasing News
Amgen plans $300M manufacturing expansion in Puerto Rico
Amgen's significant manufacturing investment in Puerto Rico strengthens domestic production capacity for critical medications while potentially creating supply chain redundancy benefits. This expansion comes as pharmaceutical companies continue reshoring efforts following pandemic-era supply disruptions and could impact drug availability and pricing for hospital purchasers. Supply chain teams should note this as part of broader industry trends toward supply chain resilience investments.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe